Misplaced Pages

Troxacitabine

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Ozzie10aaaa (talk | contribs) at 15:30, 10 February 2023 (Cleaned up using AutoEd). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 15:30, 10 February 2023 by Ozzie10aaaa (talk | contribs) (Cleaned up using AutoEd)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.
Find sources: "Troxacitabine" – news · newspapers · books · scholar · JSTOR (August 2014)
Pharmaceutical compound
Troxacitabine
Identifiers
IUPAC name
  • 4-amino-1-pyrimidin-2(1H)-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC8H11N3O4
Molar mass213.193 g·mol
3D model (JSmol)
SMILES
  • O=C1/N=C(/N)\C=C/N12O(OC2)CO
InChI
  • InChI=1S/C8H11N3O4/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m0/s1
  • Key:RXRGZNYSEHTMHC-BQBZGAKWSA-N
  (what is this?)  (verify)

Troxacitabine (brand name Troxatyl) is a nucleoside analogue with anticancer activity. Its use is being studied in patients with refractory lymphoproliferative diseases.

References

  1. Vose JM, Panwalkar A, Belanger R, Coiffier B, Baccarani M, Gregory SA, et al. (January 2007). "A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma". Leukemia & Lymphoma. 48 (1): 39–45. doi:10.1080/10428190600909578. PMID 17325846. S2CID 36220728.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: